Exobiosphere Secures LuxIMPULSE Contract to Advance Space-Based Drug Discovery

Exobiosphere has been awarded a LuxIMPULSE contract funded by the Government of Luxembourg, with technical oversight from the European Space Agency and implementation with the Luxembourg Space Agency. This support will drive the development of the Orbital High-Throughput Screener, a space-based drug discovery platform designed to expand research capabilities in oncology, regenerative medicine, and immunotherapy.

Exobiosphere has been selected to take part in the EYnovation™ program, an initiative by Ernst & Young (EY) designed to support high-potential startups and scaleups through strategic business advisory, access to an extensive network, and tailored growth acceleration services. This partnership marks another key milestone in the company’s mission to redefine drug discovery through space-based biotechnology.

LUXEMBOURG – Exobiosphere is at the forefront of biotechnology innovation, leveraging the unique conditions of space to revolutionize drug discovery. This vision takes another step forward with the addition of Dr. Bruno Santos as the Director of Research & Development.

LUXEMBOURG – Exobiosphere, a leading innovator in space-based high-throughput screening for drug discovery, is excited to announce its acceptance into the highly competitive House of BioHealth's BioIncubator in Luxembourg. With cutting-edge facilities and resources dedicated to advancing biotech, digital health, and space health innovation, this milestone enables Exobiosphere to accelerate its mission of revolutionizing drug discovery by leveraging microgravity for unprecedented breakthroughs in the pharmaceutical and biotech sectors.